Iterion Therapeutics Announces Promising Phase 1b Data for Tegavivint in Combination with Osimertinib in First-Line EGFR-Mutated Non-Small Cell Lung Cancer
Combination demonstrating 79% objective response rate (ORR), including complete responses (CRs) in 16% of patients (compared to 1% historically for osimertinib alone) Median progression-free survival (mPFS) of 19.9 months and median overall survival (mOS) of 48.8 months observed in the...